NeoGenomics Laboratories vs Veracyte
NeoGenomics Laboratories reported revenue of $727 million in fiscal 2025, 1.4 times Veracyte's $517 million in fiscal 2025. NeoGenomics Laboratories' revenue grew 10.1% in its latest year, and Veracyte's grew 16.0%. NeoGenomics Laboratories had an operating margin of -15.9%, against 11.2% at Veracyte. Free cash flow was −$22 million at NeoGenomics Laboratories and $127 million at Veracyte.
Side by side
| NeoGenomics Laboratories | Veracyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $727M | $517M |
| Revenue growth | 10.1% | 16.0% |
| Revenue growth a year, last 5 years | 10.4% | 34.5% |
| Gross margin | 43.2% | 70.1% |
| Operating margin | −15.9% | 11.2% |
| Net margin | −14.8% | 12.8% |
| Free cash flow | −$22M | $127M |
| Free cash flow margin | −3.0% | 24.5% |
| Return on capital | −8.8% | 6.1% |
| Net debt to EBITDA | — | −4.6x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.1% | 3.1% |
| Last close | $16.84 | $24.16 |
| P/E at the last close | — | 15.7× |
| Insider trades, last 12 months | sold $967,816 | sold $19.6 million |
| Piotroski F-score | 5 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NeoGenomics LaboratoriesVeracyte
Operating margin
Percent of revenue
NeoGenomics LaboratoriesVeracyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeoGenomics LaboratoriesVeracyte
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NeoGenomics Laboratories and Veracyte pages.